



Disclaimer

This presentation was prepared by NewMed Energy Limited Partnership (the "Partnership") and is given to you only for the provision of concise information for the sake of convenience and may not be copied or distributed to any other person. The Data and information included in this presentation should not be interpreted as advice and should not be relied on for any purpose. Such data and information should not be copied or used except as expressly permitted in writing.

This presentation does not purport to be comprehensive or to contain any and all information which might be relevant in connection with the making of a decision on an investment in securities of the Partnership.

No explicit or implicit representation or undertaking is given by any person regarding the accuracy or integrity of any information included in this presentation. In particular, no representation or undertaking is given regarding the realization or reasonableness of any forecasts regarding the future chances of the Partnership.

To obtain a full picture of the activities of the Partnership and the risks entailed thereby, see the full immediate and periodic reports filed by the Partnership with the Israel Securities Authority and the Tel Aviv Stock Exchange Ltd., including warnings regarding forward-looking information, as defined in the Securities Law, 5728-1968, included therein. The forward-looking information in the presentation may not materialize, in whole or in part, or may materialize differently than expected, or may be affected by factors that cannot be assessed in advance.

For the avoidance of doubt, it is clarified that the Partnership do not undertake to update and/or modify the information included in the presentation to reflect events and/or circumstances occurring after the date of preparation of the presentation.

This presentation is not an offer or invitation to buy or subscribe for any securities. This presentation and anything contained herein are not a basis for any contract or undertaking and are not to be relied upon in such context. The information provided in the presentation is not a basis for the making of any investment decision, nor a recommendation or an opinion, nor a substitute for the discretion of a potential investor.



Key Highlights

- □ 2nd quarter gas production c. 1,105 MMcf/d (195 Mboe/d), 2.81 BCM
- □ 2nd quarter earnings \$204mm EBITDA / \$137mm net profit
- Leviathan Operational Update :
 - 3rd GL project, on time on budget
 - Condensate sales
- Leviathan Expansion
 - MOE preliminary green light for additional export quantities
 - FEED commencement
 - Long lead items procurement
- □ **Dividend** \$65mm Dividend distribution for the quarter.




Production Summary

	Israel	Egypt	Jordan	Total
2Q / 2024 (BCM)	0.4	1.8	0.6	2.8
Average Price (\$/mmbtu)				6.29
2Q / 2023 (BCM)	0.3	1.6	0.6	2.5
Average Price (\$/mmbtu)				6.14






Price Environment






Leviathan Expansion

- ☐ The Ministry of Energy has given a preliminary green light to expand the export of natural gas, while also increasing the supply to the domestic market. The export volume may be increased by an additional 118 BCM, which may increase to up to 145 BCM
- Phase 1B FEED Approved a decision regarding performance of the FEED and preliminary procurement of long lead items with an additional budget of approx. \$429 million (100%, the Partnership's share is approx. \$194.5 million)
- In parallel expanding Leviathan production capacity. Regional connectivity export pipelines also progressing.
 - INGL Ashdod-Ashkelon pipeline currently expected during 2025.
 - Preliminary budgets approval by Leviathan partners for a compressor station for the expansion of the regional transmission system, expected to commence 1H 26.
 - Nitzana MOE regulation published, Leviathan allocation at third of total capacity subject to GTA signed with INGL.
- Leviathan Partners are continuing to examine additional options for an FLNG facility solution.






Increasing Regional flow Capacity





Key 2nd Quarter Financial Metrics (\$mm)






P&L Summary (\$mm)

For the period	4-6/2024	4-6/2023	2023
Revenues From natural gas and condensate sales	295.3	250.8	1,094.4
Net of royalties	42.6	36.4	159.8
Revenues, net	252.7	214.4	934.6
Expenses and costs:			
Cost of production of natural gas and condensate	43.0	34.8	148.6
Depreciation, depletion and amortization expenses	19.3	20.9	79.2
Other direct expenses	1.3	0.9	5.3
G&A	4.9	5.8	20.8
Total expenses and costs	68.5	62.4	253.9
The Partnership's share in the losses / Profits of a company accounted for at equity	1.4	(0.1)	(1.3)
Operating profit	185.6	151.9	679.4
Financial expenses	(29.4)	(31.9)	(133.8)
Financial income	23.8	6.9	28.7
Financial expenses, net	(5.6)	(25.0)	(105.1)
Profit before income taxes	180.0	126.9	574.3
Taxes on income	(43.6)	(34.0)	(142.8)
Profit from continued operation	136.4	92.9	431.5
Total profit from discontinued operations	0.6	-	2.1
Net income	137.0	92.9	433.6




2nd Quarter Change in Net Profit (\$mm)





Financial Debt (\$'B)


■ NewMed's Leviathan Bond buy back amounts to \$44mm to date





Balance Sheet Summary (\$mm)


For the Period Ending	30.06.2024	30.06.2023	31.12.2023
Assets:			
Current assets:			
Cash and cash equivalents	111.5	69.0	29.1
Short-term deposits	190.0	18.0	157.6
Trade receivables	256.1	204.9	194.5
Trade and other receivables	155.3	128.2	187.1
	712.9	420.1	568.3
Non-current assets:			
Investments in oil and gas assets	2,640.5	2,601.1	2,647.3
Investments in a company accounted for at equity	60.8	58.3	58.4
Long-term deposits	0.5	0.5	101.9
Other long-term assets	493.5	548.1	470.3
-	3,195.3	3,208.0	3,277.9
	3,908.2	3,628.1	3,846.2
Liabilities and equity:			
Current liabilities:			
Current maturities of bonds	590.5	-	-
Short term banks Loan	-	-	0.08
Income tax payable	16.3	2.1	27.7
Trade and other payables	93.2	110.7	101.1
Other short-term liabilities	0.9	6.3	2.2
	700.9	119.1	211.0
Non-current liabilities:			
Bonds	1,138.7	1,733.0	1,735.1
Deferred taxes	349.7	309.1	313.9
Other long-term liabilities	68.0	74.5	73.7
	1,556.4	2,116.6	2,122.7
Equity:			
Partners' equity	154.8	154.8	154.8
Capital reserves	(28.2)	(29.0)	(28.6)
Retained earnings	1,524.3	1,266.6	1,386.3
	1,650.9	1,392.4	1,512.5
	3,908.2	3,628.1	3,846.2



Dividends

- \$65mm profit distribution for the quarter
- \$910mm returned to unitholders in profit distribution from Leviathan start up*

Dividend Distributions



^{*} Including latest declared Dividend





Appendix



Leviathan Bond Sponsor Financial Data Report

QUARTER ENDED	30.06.2024 <u>QUANTITY/ACTUAL</u> <u>AMOUNT (IN USD\$,000)</u>
Total Offtake (BCM)	2.8
Leviathan Revenues (100%)	651,218
Loss Proceeds, if any, paid to Revenue Account	-
Sponsor Deposits, if any, into Revenue Account	-
Gross Revenues (before Royalties)	266,253
Overriding Royalties	
Statutory Royalties	(30,333)
(b) Third Party Royalties	(12,031)
Net Revenues	223,889
Costs and Expenses:	
Fees Under the Financing Documents (Interest Income)	1,292
Taxes	(28,905)
Operation and Maintenance Expenses	(41,707)
Capital Expenditures	(41,706)
Insurance (income)	(10,556)
Total Costs and Expenses (sum of Items H(a), (b), (c), (d) and (e))	(121,582)
Total Cash Flows Available for Debt Service (Item G minus Item H)	102,307
Total Cash Flow from operation (Item G minus Items H(c) and H(e)	171,262
Total Debt Service	56,438
Total Distribution to the Sponsor	49,000